COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. advances towards full FDA approval of Crofelemer for treating chemotherapy-induced diarrhea in dogs, supported by positive trial results -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Jaguar Health announces approval for reverse split at April 2026 Special Meeting of Stockholders. Stock split to begin trading on split-adjusted basis on April 30, 2026. Nasdaq grants extension for compliance with $1.00 bid price rule
